( NASDAQ-SMALL:TRPX, TelAviv:TRPX )

News from Therapix Biosciences Ltd A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 31, 2018, 16:55 ET Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update

Therapix Biosciences Ltd. (Nasdaq: TRPX) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based...


May 15, 2018, 08:31 ET Therapix Biosciences Issues CEO's Letter to Shareholders

Therapix Biosciences Ltd. (Nasdaq: TRPX) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based...


Mar 20, 2018, 08:50 ET Therapix Biosciences Announces FDA Clearance of Investigational New Drug (IND) for Phase IIa Clinical Trial of THX-110 in the Treatment of Chronic Low Back Pain

Therapix Biosciences Ltd. (NASDAQ: TRPX) ("Therapix" or the "Company"), a biopharmaceutical company focused on discovering, developing, and...


Feb 07, 2018, 08:30 ET Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected

Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty clinical-stage pharmaceutical company focusing on the...


Jan 09, 2018, 08:36 ET Therapix Biosciences Announces Expansion into Precision Medicine Through New Fully-Owned Subsidiary and Provides Corporate Update Today at the Biotech Showcase™ 2018

Therapix Biosciences Ltd. (NASDAQ: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the...


Dec 04, 2017, 08:30 ET Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program

Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based...


Nov 21, 2017, 08:30 ET Therapix Biosciences Spotlighted in Financial and Trade Media Outlets

Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the...


Nov 10, 2017, 08:30 ET Therapix Biosciences Plans Preclinical Study to Evaluate Opioid-Sparing Effects of Two Innovative Synthetic Cannabinoids

Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based...


Nov 02, 2017, 14:30 ET Therapix Biosciences Third Quarter 2017 Conference Call and Webcast Scheduled for Thursday, November 9, 2017

Therapix Biosciences Ltd. (NASDAQ: TRPX), a specialty clinical stage pharmaceutical Company specializing in the development of cannabinoid-based...


Nov 02, 2017, 08:30 ET Therapix Biosciences' Board Chairman, Ascher Shmulewitz, Appointed as Interim Chief Executive Officer

Therapix Biosciences Ltd. (NASDAQ: TRPX) ("Therapix" or the "Company"), a specialty clinical-stage pharmaceutical company developing...


Oct 18, 2017, 08:30 ET Therapix Biosciences and Assuta Medical Center to Initiate Clinical Trial in Obstructive Sleep Apnea

Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the...


Oct 06, 2017, 08:30 ET Therapix Signs Formulation Development and Clinical Manufacturing Agreement with Catalent for THX-TS01

Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the...


Sep 27, 2017, 08:30 ET Therapix's First-in-Class Therapy Demonstrates Reversal of Age-Related Cognitive Impairment in Pre-Clinical Study

Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix" or the "Company"), a specialty, clinical-stage pharmaceutical company focusing on the...


Aug 03, 2017, 08:30 ET Therapix Biosciences Second Quarter 2017 Conference Call and Webcast Scheduled for Thursday, August 10, 2017

Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical stage pharmaceutical Company specializing in the development of cannabinoid-based...


Jun 27, 2017, 16:15 ET Therapix Biosciences to Ring the Nasdaq Stock Market Opening Bell on June 28

Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical-stage pharmaceutical company specializing in the development of...


May 30, 2017, 08:24 ET Therapix Biosciences to Present at Upcoming Scientific and Investor Conferences in June

Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical stage pharmaceutical Company specializing in the development of cannabinoid-based...


May 24, 2017, 17:40 ET Therapix Biosciences Announces CEO Change

Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical stage pharmaceutical Company specializing in the development of...


May 24, 2017, 16:05 ET Therapix Biosciences Announces CEO Change

Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical stage pharmaceutical Company specializing in the development of...


May 08, 2017, 08:30 ET Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome

Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical stage pharmaceutical company specializing in the development of...


May 03, 2017, 08:30 ET Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer

Therapix Biosciences Ltd. (Nasdaq: TRPX) ("Therapix"), a specialty clinical stage pharmaceutical company specializing in the development of...


Apr 05, 2017, 08:55 ET Therapix Signs Exclusive License Agreement with Yissum for Nasal Drug Delivery Technology

Therapix Biosciences Ltd. (NASDAQ, TASE: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of...


Apr 03, 2017, 16:01 ET Therapix Biosciences Ltd. Announces Full Exercise of Underwriters' Over-Allotment Option

Therapix Biosciences Ltd. (NASDAQ: TRPX, TASE: TRPX), a specialty clinical-stage pharmaceutical company specializing in the development of...